

EDC| CDMS 2022.4 Release Certificate

Document Version: 1.0

This information is proprietary to Castor and should be treated as confidential material in accordance with existing confidentiality agreements. Unauthorized use of this data is strictly prohibited.

Release Certificate Acceptance

This is to certify that the EDC| CDMS version 2022.4 has successfully passed validation and is approved for release. Proper usage of the software enables users to be EU Annex 11 and FDA 21 CFR Part 11 compliant.

As part of the validation effort, the following documentation was produced.

Validation Documentation
EDC 2022.4 Validation Plan
EDC 2022.4 System Requirement Document
EDC 2022.4 System Design Document
EDC 2022.4 Test Cases/Results (In TestRail)
EDC 2022.4 Validation Summary Report
EDC 2022.4 Release Notes (online)
EDC 2021.x 21 CFR Part 11 Statement of Compliance
EDC 2022.4 Installation Qualification Operational Qualification
EDC 2021.x 21 CFR Part 11 Traceability Matrix

Castor successfully completed the validation effort and associated documentation and considers this a validated release. The details of the validation effort are documented in the EDC| CDMS 2022.4 Validation Summary Report. The major release was assessed for compliance with 21 CFR Part 11 and GCP.

Documentation for the previously mentioned deliverables are maintained electronically in Castor's QISMS portal and can be reviewed during audits or scheduled review sessions upon client request.

This information is proprietary to Castor and should be treated as confidential material in accordance with existing confidentiality agreements. Unauthorized use of this data is strictly prohibited.

The signatures below indicate that the validation criteria is acceptable.

QA Approval	<p>DocuSigned by: <i>Eugenia Rudzenok</i></p> <p> Signer Name: Eugenia Rudzenok Signing Reason: I approve this document Signing Time: 01-Nov-2022 1:40:15 PM CET 618646CFF724461094DB6E70D3419B06</p>
Name and Title	Eugenia Rudzenok, QA Lead

This information is proprietary to Castor and should be treated as confidential material in accordance with existing confidentiality agreements. Unauthorized use of this data is strictly prohibited.